LOS ANGELES, Dec. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key patent covering ImmunoCellular's product candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens that are commonly expressed on glioblastoma. The claims of US Patent No. 8,871,211, which issued October 28, 2014, include methods of treating neural cancer by administering a dendritic cell composition comprising peptide epitopes of the six tumor antigens of ICT-107. The claims specifically cover administration of the recited dendritic cell composition to a patient suffering from glioma, which is inclusive of glioblastoma multiforme.
"This patent provides important protection for ICT-107, and adds to ImmunoCellular's intellectual property estate for our cancer vaccine portfolio," said Andrew Gengos, ImmunoCellular Chief Executive Officer.
The ICT-107 patent was issued to Cedars Sinai Medical Center, and is exclusively licensed to ImmunoCellular Therapeutics.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully developed or commercialized, the status of the current data and whether further analyses or later studies may confirm the PFS results to date, the potential for funding and the initiation and design of phase III trials and possibility of successful results from such studies. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In this press release, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "project," "predict," "potential," "future," "intend," "certain," and similar expressions intended to identify forward-looking statements.
ImmunoCellular Therapeutics, Ltd.
SOURCE ImmunoCellular Therapeutics, Ltd.